Teva appoints new president of R&D
pharmafile | May 9, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing | Michael Hayden, R&D, Teva
Teva has appointed Dr Michael Hayden as its new president of global R&D and chief scientific officer at the firm’s HQ in Israel.
In this new role, Hayden will lead all research and development for Teva, combining the efforts of two teams focused on the development of both brand and generic medicines.
He is currently Killam Professor of medical genetics at the University of British Columbia, and Canada research chair in human genetics and molecular medicine, and is the founder and director/senior scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
As a pre-eminent expert in genetics and personalised medicine Hayden is one of the world’s leading experts on Huntington’s disease.
Dr Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Genetics.
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

ANGLE’s Parsortix system used in new cancer biology research
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour …





